IDH1 mutated acute myeloid leukemia in a child with metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria.
Anand SrinivasanYaolin ZhouTeresa ScordinoSandeep PrabhuAndrea WierengaGarfield SimonKlaas J WierengaJoel ThompsonRikin ShahArpan A SinhaPublished in: Pediatric hematology and oncology (2020)
D-2-hydroxyglutaric aciduria (D-2-HGA) is a rare metabolic disorder characterized by developmental delay, hypotonia, and bi-allelic mutations in D-2-hydroxyglutarate dehydrogenase (D2HGDH) or a single gain-of-function mutation in isocitrate dehydrogenase 2 (IDH2). Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria (MC-HGA) is a type of D-2-HGA that has been previously reported in ten patients (OMIM 614875), three of whom had somatic mosaicism for R132 variants in isocitrate dehydrogenase 1 (IDH1). We describe a 3-year-old boy with MC-HGA who subsequently developed acute myeloid leukemia (AML) and was found to have an IDH1 R132C mutation in a leukemic bone marrow sample. Further testing revealed presence of somatic mosaicism for IDH1 R132C variant, suggesting an association of IDH1 in inducing myeloid leukemogenesis.
Keyphrases
- acute myeloid leukemia
- wild type
- low grade
- bone marrow
- allogeneic hematopoietic stem cell transplantation
- copy number
- end stage renal disease
- ejection fraction
- high grade
- newly diagnosed
- chronic kidney disease
- gene expression
- prognostic factors
- single cell
- acute lymphoblastic leukemia
- patient reported outcomes
- immune response